pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma | Communications Biology
PDF) Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis
Frontiers | Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I–III Non-small Cell Lung Cancer Patients
Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes | IntechOpen
Frontiers | mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
Immunological analysis of 98 lung adenocarcinomas by targeted gene... | Download Scientific Diagram
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing - ScienceDirect
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors | bioRxiv
SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer | Nature Communications
Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives | Cell Physiol Biochem
IJMS | Free Full-Text | The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation | Oncogene
Cancers | Free Full-Text | Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis - Liu - 2020 - Cancer Communications - Wiley Online Library
Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations | medRxiv
Lung Cancer - Oncologic Disorders - Pharmacotherapy A Pathophysiologic Approach, 9th Ed.
Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations | medRxiv
![PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0cf466fd259f6bee54109793ae154a69035d609c/7-Table4-1.png "PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar")
PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar
Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives | Cell Physiol Biochem
Novel serum biomarkers for lung cancer early diagnosis and clinical outcome
Frontiers | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
IJMS | Free Full-Text | The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells | Scientific Reports
